Ramucirumab (RAM) as second-line treatment in patients with advanced hepatocellular carcinoma (HCC) and elevated baseline α-fetoprotein (AFP): An analysis of AFP kinetics in the phase III REACH-2 study.

被引：4

作者：

Finn, Richard S.

Kudo, Masatoshi

Kang, Yoon-Koo

Yen, Chia-Jui

Galle, Peter R.

Llovet, Josep

Assenat, Eric

Brandi, Giovanni

Lim, Ho Yeong

Pracht, Marc

Rau, Kun Ming

Merle, Philippe

Motomura, Kenta

Ohno, Izumi

Daniele, Bruno

Shin, Dongbok

Gerken, Guido

Abada, Paolo

Hsu, Yanzhi

Zhu, Andrew X.

机构：

[1] Univ Calif Los Angeles, Med Ctr, Los Angeles, CA 90024 USA

[2] Kindai Univ, Fac Med, Osaka, Japan

[3] Asan Med Ctr, Dept Oncol, Seoul, South Korea

[4] Natl Cheng Kung Univ Hosp, Tainan, Taiwan

[5] Univ Med, Mainz, Germany

[6] Icahn Sch Med Mt Sinai, New York, NY 10029 USA

[7] CHU Montpellier, Montpellier, France

[8] Univ Bologna, Dept Expt Diagnost & Specialty Med, Unit Oncol, Bologna, Italy

[9] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Seoul, South Korea

[10] Ctr Eugene Marquis, Rennes, France

[11] Kaohsiung Chang Gung Mem Hosp, Div Hematol Oncol, Kaohsiung, Taiwan

[12] Hop Croix Rousse, Dept Hepatol, Lyon, France

[13] Aso Iizuka Hosp, Fukuoka, Fukuoka, Japan

[14] Natl Canc Ctr Hosp East, Kashiwa, Chiba, Japan

[15] G Rummo Hosp, Benevento, Italy

[16] Gachon Univ, Gil Med Ctr, Incheon, South Korea

[17] Univ Klinikum Essen AoR, Essen, Germany

[18] Eli Lilly & Co, Indianapolis, IN 46285 USA

[19] Eli Lilly & Co, New York, NY USA

[20] Harvard Med Sch, Massachusetts Gen Hosp, Canc Ctr, Boston, MA 02115 USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2019年 / 37卷 / 04期

关键词：

D O I：

10.1200/JCO.2019.37.4_suppl.326

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

326

引用

页数：2

共 50 条

[41] Alpha-fetoprotein kinetics in patients with hepatocellular carcinoma receiving ramucirumab or placebo: an analysis of the phase 3 REACH study
Chau, Ian
Park, Joon Oh
Ryoo, Baek-Yeol
Yen, Chia-Jui
Poon, Ronnie
Pastorelli, Davide
Blanc, Jean-Frederic
Kudo, Masatoshi
Pfiffer, Tulio
Hatano, Etsuro
Chung, Hyun Cheol
Kopeckova, Katerina
Phelip, Jean-Marc
Brandi, Giovanni
Ohkawa, Shinichi
Li, Chung-Pin
Okusaka, Takuji
Hsu, Yanzhi
Abada, Paolo B.
Zhu, Andrew X.
BRITISH JOURNAL OF CANCER, 2018, 119 (01) : 19 - 26
[42] Ramucirumab for patients with advanced hepatocellular carcinoma and elevated α-fetoprotein following a non-sorafenib based first-line therapy: Final results from an expansion cohort of REACH-2
Finn, Richard S.
Yau, Thomas
Hsu, Chih-Hung
De Toni, Enrico N.
Goyal, Lipika
Galle, Peter R.
Qin, Shukui
Rao, Sujata
Sun, Fangfang
Wang, Chunxiao
Widau, Ryan C.
Zhu, Andrew X.
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
[43] Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib: Patient-focused outcome results from the randomised phase III REACH study
Chau, Ian
Peck-Radosavljevic, Markus
Borg, Christophe
Malfertheiner, Peter
Seitz, Jean Francois
Park, Joon Oh
Ryoo, Baek-Yeol
Yen, Chia-Jui
Kudo, Masatoshi
Poon, Ronnie
Pastorelli, Davide
Blanc, Jean-Frederic
Chung, Hyun Cheol
Baron, Ari D.
Okusaka, Takuji
Bowman, L.
Cui, Zhanglin Lin
Girvan, Allicia C.
Abada, Paolo B.
Yang, Ling
Zhu, Andrew X.
EUROPEAN JOURNAL OF CANCER, 2017, 81 : 17 - 25
[44] Ramucirumab for patients with advanced hepatocellular carcinoma and elevated alpha fetoprotein following a non-sorafenib based systemic therapy: interim results from an expansion cohort of the phase 3 REACH-2 study
De Toni, E. N.
Finn, R. C.
Yau, Chung Cheung T.
Yen, C. -J.
Hsu, C. -H.
Chan, S. L.
He, A. R.
Galle, P.
Trojan, J.
Stirnimann, G.
Baron, A.
Acosta-Rivera, M.
Goyal, L.
Wang, C.
Abada, P.
Widau, R.
Zhu, A. X.
ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (SUPPL 4) : 125 - 126
[45] Outcomes by baseline alpha-fetoprotein (AFP) levels in the phase III CELESTIAL trial of cabozantinib (C) versus placebo (P) in previously treated advanced hepatocellular carcinoma (HCC)
Kelley, R. K.
El-Khoueiry, A. B.
Meyer, T.
Rimassa, L.
Merle, P.
Chan, S. L.
Tran, A.
Parnis, F.
Tam, V. C.
Cattan, S.
Markby, D. W.
Clary, D. O.
Cheng, A-L.
Abou-Alfa, G. K.
ANNALS OF ONCOLOGY, 2018, 29
[46] Ramucirumab for patients with advanced HCC and elevated alpha-fetoprotein following non-sorafenib-based therapy: interim results from phase 3 REACH-2 expansion cohort
Finn, R.
De Toni, E.
Yau, T. C. C.
Yen, C. -J.
Hsu, C. -H.
Chan, S.
He, A. R.
Galle, P.
Trojan, J.
Stirnimann, G.
Baron, A.
Acosta-Rivera, M.
Goyal, L.
Wang, C.
Abada, P.
Widau, R.
Zhu, A.
SWISS MEDICAL WEEKLY, 2020, : 27S - 27S
[47] Lenalidomide for second-line treatment of advanced hepatocellular cancer (HCC): A Brown University Oncology Group phase II study.
Safran, Howard
Charpentier, Kevin
Kaubisch, Andreas
Dubel, Gregory
Perez, Kimberly
Faricy-Anderson, Katherine E.
Miner, Thomas J.
Victor, Joel
Taber, Angela Marie
Bakalarski, Pamela
Wingate, Patti
Mantripragada, Kalyan C.
Luppe, Denise
Rosati, Kayla
Espat, Joseph
Isdale, Debora
Eng, Yoko
Martel, Diane
Berz, David
Wands, Jack
JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
[48] Ramucirumab for patients with advanced hepatocellular carcinoma and elevated alpha-fetoprotein following sorafenib: Outcomes by liver disease aetiology from two randomised, placebo-controlled phase 3 studies (REACH-2 and REACH)
Galle, Peter
Kudo, Masatoshi
Llovet, Josep M.
Finn, Richard
Karwal, Mark
Denis, Pezet
Kim, Tae-You
Yang, Tsai-Sheng
Zagonel, Vittorina
Tomasek, Jiri
Phelip, Jean-Marc
Touchefeu, Yann
Koh, Su-Jin
Stirnimann, Guido
Wang, Chunxiao
Widau, Ryan
Hsu, Yanzhi
Abada, Paolo B.
Zhu, Andrew
JOURNAL OF HEPATOLOGY, 2019, 70 (01) : E46 - E46
[49] Bevacizumab combined with atezolizumab or sintilimab as second-line treatment in patients with advanced hepatocellular carcinoma: A retrospective study.
Gan, Leijuan
Li, Huikai
Wu, Qiang
Li, Qiang
Cui, Yunlong
Zhang, Wei
Fang, Feng
Lu, Wei
Li, Guangtao
Ren, Shaohua
Liu, Yayue
Lang, Mengran
Han, Ruyu
Song, Tianqiang
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 544 - 544
[50] Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial
Zhu, Andrew X.
Kang, Yoon-Koo
Yen, Chia-Jui
Finn, Richard S.
Galle, Peter R.
Llovet, Josep M.
Assenat, Eric
Brandi, Giovanni
Pracht, Marc
Lim, Ho Yeong
Rau, Kun-Ming
Motomura, Kenta
Ohno, Izumi
Merle, Philippe
Daniele, Bruno
Shin, Dong Bok
Gerken, Guido
Borg, Christophe
Hiriart, Jean-Baptiste
Okusaka, Takuji
Morimoto, Manabu
Hsu, Yanzhi
Abada, Paolo B.
Kudo, Masatoshi
LANCET ONCOLOGY, 2019, 20 (02): : 282 - 296

← 1 2 3 4 5 →